Abstract
The effect of 131I therapy as an adjunct to surgery in the management of patients with hereditary medullary carcinoma of the thyroid (MCT) was studied in 20 patients from 3 kindreds. Plasma calcitonin levels were measured before and after a dose of 131I sufficient to ablate postoperative thyroid remnants. In patients with residual biochemical MCT no significant reduction of the calcitonin levels was found after administration of radioiodine. In patients with normal postoperative calcitonin levels no (biochemical) recurrence developed 3 months to 2 yr subsequent to radioiodine therapy. It is concluded that 131I therapy as an adjunct to surgery is not indicated in the management of patients with residual hereditary MCT, although 131I may be of value in the prevention of tumor recurrence in patients with normal postoperative calcitonin values.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
